Scholar Rock to Present at 34th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., January 4, 2016 – Scholar Rock, a biotechnology company focused on discovering and developing drugs that selectively target supracellular activation of growth factors in the disease microenvironment, today announced that Nagesh Mahanthappa, PhD, President and Chief Executive Officer of Scholar Rock, will present a company overview at the J.P. Morgan 34th Annual Healthcare Conference on Tuesday, January 12, 2016, at 2:30 PM PST at the Westin St. Francis Hotel in San Francisco.

A live audio webcast of the presentation will be available on the News page of the Company’s website (https://investors.scholarrock.com/investors-media/press-releases). A replay of the webcast will also be available from Scholar Rock’s website within 48 hours after the event.

About Supracellular Activation
Scholar Rock was founded on unique insights into the mechanism of supracellular activation of growth factors, a newly elucidated mechanism by which nature regulates growth factor activation in complex disease microenvironments. Through modulation of supracellular activation, highly specific and localized efficacy at the site of disease can be achieved, overcoming the challenges that have limited the traditional approach of inhibiting growth factors systemically. Scholar Rock is the first company to exploit this mechanism to discover and develop a pipeline of potential best-in-class therapeutic candidates.

About Scholar Rock
Scholar Rock is a biotechnology company focused on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The Company’s initial proprietary and partnered drug discovery programs target specific growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology and autoimmune diseases. Scholar Rock was founded upon discoveries made by its scientific founders, Professors Timothy Springer, PhD, and Leonard Zon, MD, of Boston Children’s Hospital and Harvard Medical School, related to the molecular mechanisms of supracellular activation. The company is backed by leading investors, including Polaris Partners, Timothy Springer, ARCH Venture Partners, Fidelity Investments, EcoR1 Capital, The Kraft Group, and Cormorant Asset Management.

Investor Contact:
Stephanie Ascher
Stern Investor Relations, Inc.
Tel: 212-362-1200
stephanie@sternir.com

Media Contact:
Kathryn Morris
The Yates Network
Tel: 845-635-9828
kathryn@theyatesnetwork.com